III. Identification of novel CXCR3 chemokine receptor antagonists with a pyrazinyl-piperazinyl-piperidine scaffold

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 23, 2011, Pages 6982-6986

  Kim, Seong Heon ^a   Anilkumar, Gopinadhan N ^a   Zawacki, Lisa Guise ^b   Zeng, Qingbei ^a   Yang, De Yi ^a   Shao, Yuefei ^b   Dong, Guizhen ^b   Xu, Xiaolian ^b   Yu, Wensheng ^a   Jiang, Yueheng ^a   Jenh, Chung Her ^a   Hall III, James W ^b   Carroll, Carolyn Diianni ^b   Hobbs, Doug W ^b   Baldwin, John J ^b   McGuinness, Brian F ^b   Rosenblum, Stuart B ^a   Kozlowski, Joseph A ^a   Shankar, Bandarpalle B ^a   Shih, Neng Yang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Ligand Pharmaceuticals   (United States)

Author keywords

Chemokine; CXCR3; GPCR

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; MOLECULAR SCAFFOLD; PIPERAZINE; PIPERIDINE; POTASSIUM CHANNEL HERG; PYRAZINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG STRUCTURE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN BINDING; PYRAZINES; RATS; RECEPTORS, CXCR3; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 80255129399     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.120     Document Type: Article

References (16)

1. L. Liu, M.K. Callahan, D. Huang, and R.M. Ransohoff Curr. Top. Dev. Biol. 68 2005 149
2. J.E. Turner, O.M. Steinmetz, R.A. Stahl, and U. Panzer Mini-Rev. Med. Chem. 7 2007 1089
3. M. Loetscher J. Exp. Med. 184 1996 963
4. K.E. Cole J. Exp. Med. 187 1998 2009
5. A. Szczuciński, and J. Losy Acta Neurol. Scand. 115 2007 137
6. For reviews of small molecule CXCR3 antagonists see: M. Wijtmans, D. Verzijl, R. Leurs, I.J.P. de Esch, and M.J. Smit Chem. Med. Chem. 3 2008 861
7. T.L. Collins, M.G. Johnson, and J.C. Medina Chem. Biol. Basic Res. Clin. Appl. 2 2007 79
8. J.C. Medina, M.G. Johnson, and T.L. Collins Annu. Rep. Med. Chem. 40 2005 215
9. B.F. McGuinness, C.D. Carroll, L.G. Zawacki, Z. Dong, C. Yang, D.W. Hobbs, J.-S. Biji, J.W. Hall III, C.-H. Jenh, J.A. Kozlowski, G.N. Anilkumar, and S.B. Rosenblum Bioorg. Med. Chem. Lett. 19 2009 5205
10. Y. Shao, G.N. Anilkumar, C.D. Carroll, G. Dong, J.W. Hall III, D.W. Hobbs, Y. Jiang, C.-H. Jenh, S.H. Kim, J.A. Kozlowski, B.F. McGuinness, S.B. Rosenblum, I. Schulman, N.-Y. Shih, Y. Shu, M.K.C. Wong, W. Yu, L.G. Zawacki, and Q. Zeng Bioorg. Med. Chem. Lett. 21 2011 1527
11. Compound 8a has been selected for the proof-of-concept (POC) evaluation in a rat EAE model. Jenh, C.-H., et al., manuscript in preparation.
12. R.J. Vaz, Y. Li, and D. Rampe Prog. Med. Chem. 43 2005 1
13. C.A. Blum, X. Zheng, and S. De Lombaert J. Med. Chem. 47 2004 2318
14. Zeng, Q.; Yang, D.-Y.; Rosenblum, S. B.; Wong, M. K. C.; Anilkumar, G.; Kim, S. H.; Yu, W.; Kozlowski, J. A.; Shih, N.-Y.; McGuinness, B. F.; Zawacki, L. G.; Hobbs, D. W. WO Patent 2006/091428.
15. 50's are the mean values (n = 2) with SD of ∼13%. For reference see: C.-H. Jenh, M.A. Cox, W. Hipkin, T. Lu, C. Pugliese-Sivo, W. Gonsiorek, C.-C. Chou, S.K. Narula, and P.J. Zavodny Cytokine 15 2001 113
16. 2(S)-Ethyl-5(R)-ethylpiperazine was purchased from the commercial source.